Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites, foods, medications, and other causes. The epinephrine auto-injectors are disposable, prefilled automatic injection devices, which are intended for self-administration of epinephrine solution in an emergency for on-the-spot treatment during early onset of symptoms of an anaphylactic reaction.
Market Dynamics
Increasing prevalence of food allergies is a major factor driving epinephrine market growth. According to a research conducted by the Centers for Disease Control and Prevention (CDC) in 2013, in the U.S., from 1997 to 2011, food allergies among children increased around by 50%. Moreover, according to the European Academy of Allergy and Clinical Immunology (EAACI), over 17 million people in Europe were affected by food allergy in 2015. For instance, in November 2017, Kaléo, Inc. received the FDA approval for its supplemental New Drug Application (sNDA) for AUVI-Q, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds.
Key features of the study:
- This report provides in-depth analysis of the epinephrine market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global epinephrine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Mylan N.V., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals Corporation, Bausch Health Companies, ALK- Abello A/S
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global epinephrine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the epinephrine market
Detailed Segmentation:
- Global Epinephrine Market, By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- Global Epinephrine Market, By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- Global Epinephrine Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Epinephrine Market, By Geography:
- North America
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
- By Application:
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Mylan N.V.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Impax Laboratories, Inc.
- Kaleo, Inc.
- Adamis Pharmaceuticals Corporation
- Bausch Health Companies
- ALK- Abello A/S
“*” marked represents similar segmentation in other categories in the respective section.
